



HAL
open science

Electrokinetic characterization of extracellular vesicles with capillary electrophoresis: A new tool for their identification and quantification

Marco Morani, Thanh Duc Mai, Zuzana Krupova, Pierre Defrenaix, Evgen Multia, Marja-Liisa Riekkola, Myriam Taverna

► To cite this version:

Marco Morani, Thanh Duc Mai, Zuzana Krupova, Pierre Defrenaix, Evgen Multia, et al.. Electrokinetic characterization of extracellular vesicles with capillary electrophoresis: A new tool for their identification and quantification. *Analytica Chimica Acta*, 2020, 1128, pp.42 - 51. 10.1016/j.aca.2020.06.073 . hal-03491265

HAL Id: hal-03491265

<https://hal.science/hal-03491265>

Submitted on 18 Jul 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Electrokinetic characterization of extracellular vesicles with capillary electrophoresis: a**
2 **new tool for their identification and quantification**

3

4 **Marco Morani¹, Thanh Duc Mai¹, Zuzana Krupova², Pierre Defrenaux², Evgen Multia³,**
5 **Marja-Liisa Riekkola³ and Myriam Taverna^{1,4*}**

6

7 ¹ *Institut Galien Paris Sud, UMR 8612, Protein and Nanotechnology in Analytical Science*
8 *(PNAS), CNRS, Univ. Paris-Sud, Univ. Paris-Saclay, 5 rue Jean Baptiste Clément, 92290*
9 *Châtenay-Malabry, France*

10 ² *Excilone - 6, Rue Blaise Pascal - Parc Euclide - 78990 Elancourt - France*

11 ³ *Department of Chemistry, P.O. Box 55, FI-00014 University of Helsinki, Finland.*

12 ⁴ *Institut Universitaire de France (IUF)*

13 **Correspondence:** E-mail: myriam.taverna@u-psud.fr; Fax: +33-1-46-83-54-62

14

15

16 **Keywords:** capillary electrophoresis; LIF detection; membrane labeling; extracellular vesicles

17

18

19

20 *Abbreviations:* EVs, extracellular vesicles; CE, capillary electrophoresis; LIF, laser-induced
21 fluorescence; DLS, dynamic light scattering; NTA, nanoparticle tracking analysis; PVA,
22 polyvinyl alcohol; AsFIFFF, Asymmetrical flow field-flow fractionation; MALS, multi angle
23 light scattering; ISF BGE, inorganic-species-free background electrolyte; SEC, size exclusion
24 chromatography.

25

26

27

28 **Abstract**

29 This work reports on the development of the first capillary electrophoresis methodology for
30 the elucidation of extracellular vesicles' (EVs) electrokinetic distributions. The approach is
31 based on capillary electrophoresis coupled with laser-induced fluorescent (LIF) detection for
32 the identification and quantification of EVs after their isolation. Sensitive detection of these
33 nanometric entities was possible thanks to an 'inorganic-species-free' background electrolyte.
34 This electrolyte was made up of weakly charged molecules at very high concentrations to
35 stabilize EVs, and an intra-membrane labelling approach was used to prevent EV morphology
36 modification. The limit of detection for EVs achieved using the developed CE-LIF method
37 reached 8×10^9 EVs / mL, whereas the calibration curve was acquired from 1.22×10^{10} to
38 1.20×10^{11} EVs / mL. The CE-LIF approach was applied to provide the electrokinetic
39 distributions of various EVs of animal and human origins, and visualize different EV
40 subpopulations from our recently developed high-yield EV isolation method.

41

42

43

44

45

46

47

48

49

50

51

52 **1. Introduction**

53 Extracellular vesicles (EVs) are a common family of heterogeneous small vesicles secreted by
54 all types of cells. [1, 2]. EVs contain distinct subsets of molecules characteristic of the mother
55 cells from which they are secreted, conveying, in this way, many vital signals under normal
56 or pathological conditions. This makes them useful for biomarker discovery and much current
57 research is focusing on them for their potential diagnostic and prognostic applications [3-5].
58 Despite overt evidence of the potential of EVs in clinical diagnostic practice, guidelines for
59 analytical procedures have not yet been properly established. The isolation and enrichment of
60 EVs from biofluids remains a challenging prerequisite before light can be shed on the target
61 exosomal molecules (e.g. nucleic acids, proteins, growth factors, cytokines etc.) that are
62 present in trace amounts. After this has been achieved, it is critical to verify the identity of
63 EVs and monitor their purity and concentration.

64 Until now, most common physical characterization approaches have relied on microscopy-
65 based methods, dynamic light scattering (DLS), nanoparticle tracking analysis (NTA) and
66 tunable resistive pulse sensing vesicle flow cytometry (see [6, 7]). To a lesser extent,
67 immunoaffinity-based methods, notably enzyme-linked immunosorbent assays (ELISA) and
68 amplified luminescent proximity homogeneous assay on beads (ExoScreen), have been
69 employed to identify EVs' subpopulations from different cellular origins [8, 9]. Each
70 technique can provide only part of the information sets required for the confirmation and
71 characterization of target EVs. EVs identification can also be done via analyses of exosomal
72 lysates (e.g. immunoblotting or mass spectrometry for intra-exosomal proteins [6], or
73 Fluorocet kit to measure esterase activity released from lysed EVs [10]). Nevertheless, with
74 such bulk measurements, the differentiation between small cells, debris and EVs may not be
75 possible, and information on size and charge is not provided. To have access to reliable and
76 fast identification and characterization of EVs, continued efforts have been directed toward
77 the development of novel technologies. The most recent communications reported on

78 exosome luminescent quantification [11] and electrical detection of polarized exosomes via
79 capacitance-voltage measurements [12].

80

81 A satisfactory method should meet all the criteria for EV phenotyping, notably the ability to
82 discriminate between different size sub-populations and to maintain EV integrity during
83 analysis. High detection sensitivity in some cases is desirable, for example when working
84 with EVs from cerebrospinal fluids, as their concentration after extraction may be very low.
85 Till now, no single method has succeeded in meeting all of these criteria simultaneously or
86 that can be used universally in a variety of infrastructures (i.e. depending on the equipment
87 and expertise to hand). To provide sufficient physical and biological information on isolated
88 EVs many complementary techniques have to be used. From this rationality, capillary
89 electrophoresis (CE), which has shown its capability to provide nanoparticle analysis and
90 characterization [13], emerges as an interesting and unexplored alternative to elucidate the
91 electrokinetic distribution of nanoscaled EVs. The only electrokinetic approach, based on
92 electrophoretic light scattering, was exploited by Ichiki's group for tracking exosomes and
93 measuring their zeta potential, using a microchip format coupled with a laser dark-field
94 microscope [14-16]. In addition, specific purpose-made instrumentation and manual operation
95 are required for this new application.

96

97 Herein we report for the first time the use of CE coupled with laser-induced fluorescent (LIF)
98 detection for the identification and quantification of EVs after their isolation. To this purpose,
99 strategies for fluorescent labeling of EVs, EVs matrix substitution as well as background
100 electrolyte optimization were developed. Then the developed CE-LIF method was employed
101 to study the electrokinetic distribution of EVs isolates obtained from using various techniques,
102 including the recently developed approach for high-yield EV isolation from human plasma

103 [17]. After the submission of our manuscript on CE-LIF of EVs, another work on CE-UV of
104 EVs was published [18]. Together with this pioneering work, we provide herein the first
105 proof of concept on electrokinetic separation and characterization of EVs.

106

107 **2. Materials and methods**

108 ***2.1. Chemicals and reagents***

109 2-(Cyclohexylamino)ethanesulfonic acid (CHES), phosphate buffered saline (PBS 10x),
110 sodium dodecyl sulfate (SDS, 98.5% (GC)), Tris(hydroxymethyl)aminomethane (Tris) and
111 sodium acetate, anhydrous Na₂CO₃, NaHCO₃, and phosphate buffer saline tablets (PBS)₂ were
112 all obtained from Sigma Aldrich (St. Louis, MO, USA). Sodium hydroxide (1 M),
113 hydrochloric (1 M) and acetic (99.9% purity) acids were obtained from VWR (Fontenay-sous-
114 Bois, France). All buffers were prepared with deionized water. Vybrant™ CFDA SE Cell
115 Tracer Kit (dye 5-(and-6)-Carboxyfluorescein diacetate succinimidyl ester, CFDA-SE) was
116 purchased from Thermo Fisher Scientific (Waltham, MA, USA). 25% (v/v) ammonia was
117 obtained from Riedel-de Haën (Seelze, Germany). CD9 Monoclonal Antibody (eBioSN4
118 (SN4 C3-3A2)), eBioscience™ was purchased from Thermo Fisher Scientific and purified
119 mouse anti-human CD61 (clone VI-PL2) antibody was purchased from BD Biosciences (San
120 Jose, CA, USA). CIM® CDI -0.34 mL disks and the disk housing were purchased from BIA
121 Separations (Ajdovščina, Slovenia). Healthy human plasma for immunoaffinity isolations of
122 EVs was obtained from Finnish Red Cross Blood Service (Helsinki, Finland). EVs samples of
123 different purity degrees isolated from bovine milk, pony plasma, pony serum, and human
124 plasma were provided by Excilone (Elancourt, France).

125

126 ***2.2. Apparatus and Material***

127 The CE-LIF studies were performed with a PA 800 Plus system (Sciex Separation, Brea, CA)
128 equipped with a solid-state laser induced fluorescence detector ($\lambda_{\text{excitation}}$: 488 nm, $\lambda_{\text{emission}}$: 520
129 nm) purchased from Integrated Optics (Art. No. 40A-48A-52A-64A-14-DM-PT, distributed
130 by Acal BFi, Evry, France). Uncoated fused silica capillaries were purchased from CM
131 Scientific (Silsden, UK). Polyvinyl Alcohol (PVA) neutral capillaries were obtained from
132 Sciex. Data acquisition and instrument control were carried out using Karat 8.0 software
133 (Sciex Separation, Brea, CA). Deionized water used in all experiments was purified using a
134 Direct-Q3 UV purification system (Millipore, Milford, MA, USA). Conductivity and pH
135 values of buffer solutions and samples were obtained with a SevenCompact pH meter (Mettler
136 Toledo, Schwerzenbach, Switzerland). Preparation of background electrolyte (BGE) and
137 buffer ionic strength (IS) calculations were based on simulations with the computer program
138 PhoeBus (Analis, Suarlée, Belgium).

139 Asymmetrical flow field-flow fractionation (AsFIFFF) system used was from Postnova
140 Analytics (AF2000 system, Landsberg, Germany). It was equipped with 350 μm spacer
141 (Postnova Af2000 MF) and a 10 kDa mass cut-off regenerated cellulose membrane (Postnova
142 AF2000 MT series) in a kite shaped channel ($L_{\text{tot}}=27.5$ cm). The channel was followed by UV
143 (SPD-20A Prominence, Shimadzu, Japan), multi-angle light scattering (MALS) (BI-MwA
144 Molecular Weight Analyzer, USA), and DLS (Zetasizer Nano, Malvern Instruments, UK)
145 detectors. The fractions were collected with CBM-20A modular system controller (Shimadzu,
146 Japan) and FRC-10A fraction collector (Shimadzu, Japan). Fractions were further lyophilized
147 for EVs enrichment using Heto PowerDry LL1500 freeze dryer (Thermo Scientific).

148

149 **2.3. Methods**

150 *Isolation of bovine milk-derived EVs with sucrose gradient ultracentrifugation*

151 Whole bovine milk samples were centrifuged at 3,000 x g for 30 min at 4°C (Allegra X-15R,
152 Beckman Coulter, France) to separate fat from skimmed milk. The whey was obtained after
153 acid precipitation of milk (50 mL) with 5 mL of 10% acetic acid and incubation at 37 °C for
154 10 minutes. This was then continued by addition of 5 mL of 1 M sodium acetate, and
155 incubation for 10 minutes at RT. This was followed by centrifugation at 1500 x g, 4°C for 15
156 min and filtration of supernatant using vacuum-driven filtration system Millipore Steritop,
157 0.22 µm. The whey supernatants were concentrated by centrifugation at 4,000 x g and 20°C
158 using Amicon 100kDa centrifugal filter units (Merck Millipore). The obtained retentate was
159 ultra-centrifuged for pelleting the EVs at 100 000 x g for 1h10 at 4°C (Beckman Coulter,
160 Optima XPN-80, 50TI rotor). The pellets were solubilized in 500 µL of PBS then added to 11
161 mL of pre-prepared sucrose gradient 5-40% and ultra-centrifuged at 200 000 x g for 18h at
162 4°C (Beckman Coulter, Optima XPN-80, SW41 rotor). Selected fractions corresponding to
163 EVs' flotation densities (1 mL) were collected, diluted in 6 mL of PBS 1x and finally
164 centrifuged at 100 000 x g for 1h10 at 4°C (Beckman Coulter, Optima XPN-80, 50TI rotor).
165 The pellets were resuspended in 50 µL of PBS 1x and stored at -80°C, until further analyses.
166 Bovine milk-derived EVs with narrow size distribution, well-determined concentrations and
167 characterized with dynamic light scattering (DLS), nanoparticle tracking analysis (NTA),
168 transmission electron microscopy (TEM) as well as proteomic profiling were used as EV
169 standards for CE-LIF methodology development.

170

171 *Isolation of pony plasma/serum and human plasma derived EVs with size exclusion*
172 *chromatography (SEC)*

173 *Preparation of plasma:* Peripheral blood was collected into EDTA-coated vacutainer tubes.
174 After ten-time inversion, samples were processed within the 60 minutes of collection.
175 Consecutive centrifugation steps at 2,500 x g, 4°C for 15 minutes and then at 15 000 x g for

176 10 minutes were performed followed by filtration of the supernatant through 0.22µm filters.

177 *Preparation of serum:* Whole blood was collected into anticoagulant-free tubes and allowed
178 to clot at room temperature for 45 minutes. The clot was removed by centrifuging at 3 200
179 x g, 4°C for 15 minutes, followed by centrifugation at 15 000 x g, 4°C for 10 minutes and
180 filtration of the supernatant through 0.22 µm filters.

181 500 µl of pre-treated plasma/serum was loaded onto a qEVoriginal SEC column (Izon
182 Science, New Zealand) previously washed and equilibrated with PBS. Fraction collection
183 (0.5 mL per fraction) was carried out immediately using PBS as elution buffer. The selected
184 elution fractions were pooled and were subsequently concentrated using 100 kDa Amicon
185 centrifugal filter units (Merck Millipore). Post-treatment processing with several washing
186 steps with PBS was applied to obtain highly pure EV fractions.

187

188 *Isolation of human plasma derived EVs with monolithic disks via immunoaffinity*
189 *chromatography*

190 EVs were isolated from human plasma using a recently developed monolithic affinity
191 chromatography approach [17]. Briefly, diluted human plasma samples (250 µL of plasma
192 diluted to 5 mL in PBS) were percolated through monolithic disk columns immobilised with
193 either anti-human CD61 or anti-human CD9 antibodies. The enriched EVs were eluted with 2
194 mL of either ammonium hydroxide (NH₄OH, pH 11.3) or carbonate-bicarbonate (pH 11.3)
195 solution after washing the unbound plasma with 3 mL of PBS. The ammonium hydroxide
196 solution was prepared by diluting 2.26 mL of 25% ammonia to a final volume of 100 mL
197 with Milli-Q water. The carbonate-bicarbonate solution was prepared by mixing 90 mL of 0.1
198 M Na₂CO₃ stock solution (1.06 g of anhydrous Na₂CO₃ dissolved in 100 mL of Milli-Q
199 water) with 10 mL of 0.1 M NaHCO₃ stock solution (0.84 g of NaHCO₃ in 100 mL of Milli-
200 Q water) and adjusting the pH to 11.3 with 200 µL of 5 M NaOH. The pH of the isolates

201 (final volume 0.5 mL) was adjusted by addition of 50 μ L of 1 M HCl prior to characterization
202 with Lowry method [19], NTA, Western blotting, and TEM [20]. The results of these
203 characterizations can be found in our previous study [17].

204 Asymmetrical flow field-flow fractionation (AsFIFFF) coupled with UV, multi-angle light
205 scattering (MALS) and flow DLS detectors were used to characterize and fractionate
206 subpopulations of the eluents. EV isolation and characterization were performed using the
207 protocol recently published [17] with some modifications. Briefly, 500 μ L was injected with a
208 flow of 0.1 mL/min over 5 min during the focus mode at the cross-flow rate of 3 mL/min.
209 Detector flow rate was 0.5 mL/min and PBS was used as a running buffer. After the focusing
210 step and 1 min of transition time, a 2 min linear decrease in cross-flow to 0.5 mL/min was
211 implemented, followed by a linear decrease over 1 min to 0 mL/min. The run was continued
212 for 15 min with only the detector flow (0.5 mL/min), followed by a rinse step (0.5 mL/min)
213 for 2 min, making a total run time of 26 min. EV fractions (300 μ L each) provided by
214 AsFIFFF were frozen and subsequently lyophilized over 3 hours at temperature of -110°C .
215 Before starting the labelling protocol, the fractions were rehydrated with 30 μ L PBS for EVs
216 enrichment.

217

218 *Dynamic Light Scattering (DLS) of extracellular vesicles*

219 Size distribution and zeta potential of EVs were measured using a Zetasizer Nano (Malvern
220 Instruments, Malvern, UK). All measurements, using PBS as the dispersant, were undertaken
221 in triplicates at 25°C with scattering angle of 90° and refractive index of 1.332. Data
222 processing and analysis were performed in the automatic mode with at least 13 measurements
223 per run using Zetasizer software version 7.11.

224

225 *Nanoparticle Tracking Analysis (NTA) of extracellular vesicles*

226 Size distribution and particle concentration were determined with either Nanoparticle
227 Tracking Analysis (NTA) systems: Zetaview (Particle Metrix, Germany) or Nanosight
228 (Malvern Instruments, UK). All experiments were carried out with pre-diluted samples in
229 PBS according to input sample concentrations, leading to particle concentration within the 10^7
230 - 10^9 particles per mL range for optimal analysis.

231 The Zetaview system (Particle Metrix) was equipped with a 488 nm laser. Each experiment
232 was performed in duplicate on 11 different positions within the sample cell with following
233 specifications and analysis parameters: sensitivity 60, shutter 100, Max Area 100, Min Area 5,
234 Min Brightness 25. The results were validated while obtaining at least 1 000 valid tracks for
235 each run. For data capture and analysis, the Nanoparticle Tracking Analysis Software (NTA)
236 vs 8.05.04 was used.

237 Particle concentration and size distribution were also determined with a Nanosight NS300
238 instrument (Malvern, version NTA 3.2 Dev Build 3.2.16) equipped with a 405 nm laser,
239 sCMOS camera type and the NTA software v3.1. The video acquisition was performed using
240 a camera level of 14. Per sample, 3 videos of 90 seconds with a frame rate of 30 frames/s
241 were captured at 25°C and subsequently analyzed with a threshold set up at 5. The results
242 were validated with at least 2,000 valid tracks for each triplicate.

243

244 *Fluorescent labelling of EVs*

245 The fluorescently labelled EVs were prepared using the 5-(and-6)-Carboxyfluorescein
246 diacetate succinimidyl ester (CFDA-SE). The CFDA-SE stock solution (10 mM) was
247 prepared in DMSO following the manufacturer's instructions. Prior to staining, the working
248 solution was diluted to 200 μ M in PBS. 20 μ L of EVs was mixed with 20 μ L of 200 μ M
249 CFDA-SE solution (resulting in a final CFDA-SE concentration of 100 μ M), and incubated
250 for 2h in the dark at 37°C with gentle shaking.

251

252 *Matrix substitution of EVs*

253 Labelled EVs were obtained from two different matrix exchange approaches, using either
254 centrifugal filtration on Nanosep Omega Membranes 3K (PALL Life Sciences, Port
255 Washington, NY, USA) or EVs filtration with commercial Exosome Spin Columns (MW
256 3000) obtained from Thermo Fisher Scientific (Waltham, MA USA). The first approach
257 (centrifugal filtration) was carried out by addition of the desired buffer to be substituted on the
258 top of the labelled EVs, then centrifugal spinning of the column for approximately 4 minutes
259 at 5000 x g. This process was repeated four times. In the last step, a buffer volume equivalent
260 to that of labelled EVs was used to maintain the same concentration before and after filtration.
261 The second approach was carried out according to the manufacturer's instructions.

262

263 *CE-LIF of fluorescently labelled EVs and EOF measurement*

264 The fused silica capillary (I.D. of 50 μm , O.D. of 375 μm effective length (L_{eff}) of 50.2 cm
265 and total length (L_{tot}) of 60.2 cm) was pre-conditioned (using a pressure of 172 kPa at the
266 capillary inlet) with the following sequence: water for 10 min, 1 M NaOH for 10 min, 1 M
267 HCl for 10 min and then water for 10 min. The rinsing between two analyses was carried out
268 with 50 mM SDS for 5 min, 1 M NaOH for 5 min, deionized water for 5 min, and finally the
269 running BGE for 5 min using a pressure of 207 kPa. A plug of sample was hydrodynamically
270 injected from the inlet end by applying a pressure of 3.4 kPa for 2 min. The separation was
271 carried out under 25 kV (normal polarity) at 25 °C and the samples were maintained at 5 °C
272 with the sample storage module of the PA 800 Plus equipment. The optimized BGE was
273 composed of Tris / CHES (IS 90 mM, pH 8.4). This BGE was prepared as follows. First two
274 stock solutions of 1.5 M Tris and 1.2M CHES were prepared by dissolving 1.817 g of Tris
275 base in 10 mL of water and 10.447 g of CHES in 42 mL of water. Then, 8 mL of 1.5 M Tris

276 was mixed with 41.09 mL of 1.2 M CHES. Deionized water was then added to a total volume
277 of 50 mL. pH of the BGE after preparation was confirmed with a pH meter.
278 The calibration curve was acquired using bovine milk derived EV standards. The EVs isolates
279 were diluted with 1X PBS to prepare different initial EVs concentrations from 1.65×10^{10} to
280 1.65×10^{11} EVs / mL before the labeling and matrix removal on spin columns. 20 μ L of EVs
281 was mixed with 20 μ L of CFDA-SE 200 μ M solution (resulting in a final CFDA-SE
282 concentration of 100 μ M CFDA-SE), and incubated for 2 h at 37°C. Then 40 μ L of labelled
283 EVs was loaded into EV Spin Columns and recovered in Tris / CHES 90 mM. Calculations
284 for final concentrations were based on initial concentration measured by NTA before the
285 labeling and taking into account a recovery of 75 % from the matrix substitution step. EO
286 mobility was measured with CE-LIF using 4-(4-Methoxybenzylamino)-7-nitro-2,1,3-
287 benzoxadiazole (MBD, used as an EOF marker) which is a neutral and fluorescent compound
288 [21]. The EOF marker was dissolved in a DMSO:CH₃OH (1:1 v/v) solution to a concentration
289 of 20mM, and then further diluted to 2 mM in BGE before use.

290

291 **3. Results and Discussion**

292 **3.1. Fluorescent labeling of EVs**

293 Our preliminary attempts to determine EVs with CE-UV showed insufficient sensitivity in
294 detecting low-abundant milk EVs purified by ultracentrifugation and suspended in PBS. To
295 improve the detection sensitivity and specificity, an effort was made to specifically tag EVs
296 with a fluorescent dye for CE-LIF analysis. Among the different available strategies for the
297 fluorescent labelling of EVs [22-25], the intra-membrane labelling approach using CFDA-SE,
298 initially applied for flow cytometry of EVs derived from dendritic cell lines, was reported to
299 result in no changes in size or charge of EVs [25]. This approach also avoided previous issues
300 encountered with lipophilic dyes that form dye aggregates or micelles with similar signals to

301 those of EVs , thereby inducing misleading data [26]. This intracellular covalent protein
302 tagging method was therefore adapted to CE-LIF with further optimisations to label EVs.
303 Different parameters, including incubation temperature, duration, dye concentration as well as
304 agitation mode and speed, were optimized to achieve the highest difference between LIF
305 signals of milk EVs samples and those from blanks (see Fig. S1 in the Electronic
306 Supplementary Information ESI). We observed that EVs staining reached the saturation at dye
307 concentrations higher than 200 μ M (Fig. S1 A). By varying the EVs dye incubation time from
308 30 min to 12 hours, it was found that much longer incubation times (at least 2 hours) were
309 required for EVs labelling than those normally used for cell labelling with CFDA-SE (5-15
310 min) [27]. This is presumably due to differences in size and esterase expression. Too long
311 incubation time on the other hand resulted in lower signal-to-noise ratio in a time-dependent
312 manner (Fig. S1 B), possibly due to EVs lysis or breaking of the covalent linkage in
313 fluorescent dye over long time. Optimal conditions for EVs labelling with CFDA-SE were set
314 at 37 °C, 2 hours of incubation, and shaking at 300 rpm. Quality control of CFDA-SE labelled
315 EVs using DLS and NTA (see Fig. S2) revealed no significant change in size distributions
316 (153 nm vs 147 nm), surface charges (-14.8 mV vs -15.4 mV), nor concentrations of EVs
317 (determined with NTA) before and after labelling.

318

319 **3.2. CE-LIF of fluorescently labelled EVs**

320 CE-LIF method development was first conducted with bovine milk-derived EVs isolated with
321 sucrose gradient ultracentrifugation and suspended in phosphate-buffered saline (PBS) buffer.
322 Keeping the EVs in PBS during CE separation represents the best-case scenario to maintain
323 both physiological pH and isotonic conditions. This allowed us to focus on BGE optimization
324 by reducing the risk of EVs loss or lysis induced from sample treatment steps. Several issues
325 were however encountered during our preliminary tests using conventional BGEs for CE-LIF

326 (*i.e.* phosphate, borate, and Tricine/NaOH buffers). High conductivity of the PBS matrix of
327 the samples was detrimental to CE stacking and separation, and adsorption of EVs to capillary
328 wall led to undetectable and irreproducible signals. An effort was then made to exploit
329 ‘inorganic-species-free’ (ISF) BGEs containing concentrated weakly charged molecules,
330 which have recently been found to improve the performance of CE-LIF for proteins and
331 peptides [28]. While both constituents of the ISF BGE used in this work are well known, the
332 novelty lies in the use of unprecedentedly high concentrations (several hundred mM) of these
333 large weakly charged molecules. Such high concentrations, while not favorable for
334 conventional UV detection due to elevated background signal, were found advantageous for
335 CE-LIF of EVs. This BGE at very high concentrations reduced spikes provoked by EVs
336 aggregation / collision during electrophoresis, which was observed with other conventional
337 BGEs. Interestingly, this observation was also reported in the recently released work on CE-
338 UV of EVs, in which large ions (*i.e.* bis-tris propane ions) were employed to maintain the EV
339 signal stability [18]. The ISF BGEs, which are tolerant to the presence of PBS in the sample
340 matrix, were found to minimize protein adsorption to capillary wall and induce excellent
341 stacking of slowly migrating proteins. They were expected to provide similar positive features
342 when applied to EVs. The separations of labelled EVs from the abundant residual
343 fluorophores in the PBS matrix are shown in Fig. 1. The ISF BGE was made up of Tris /
344 CHES (pH 8.4) at different ionic strengths (50- 150 mM). The use of extremely high BGE
345 concentrations (630 mM Tris and 870 mM CHES, IS: 150 mM) was still possible without
346 generating high current intensity (only 30 μ A under 25kV). Under the working conditions, the
347 negatively charged EVs transported by an elevated EO mobility migrated faster than the
348 residual CFDA-SE. The EO mobility was tuned from 26×10^{-9} to 12×10^{-9} $\text{m}^2 \cdot \text{V}^{-1} \cdot \text{s}^{-1}$ by
349 increasing IS from 50 to 150 mM. Under an IS of 90 mM (Fig. 1B), labelled EVs and CFSE
350 fluorophore were much better separated than with IS of 50 mM (Fig. 1A), whereas the EV

351 peak shape was not too broadened as was the case when observed with IS of 150 mM (Fig.
352 1C). Sufficient resolution between EVs and CFSE fluorophore was needed to avoid peak
353 overlapping due to a time-dependent increase in CFSE fluorophore peak. Indeed, CFSE-
354 protein conjugates can exit EVs or become degraded over time [29]. Peaks of EVs were broad
355 and many spikes appeared in the profile. To understand the origin of these events, the analysis
356 was performed with a commercial PVA neutral coating, using the same BGE. As can be seen
357 in Fig. 2, EVs peaks were still broad, this phenomenon being even more pronounced with the
358 PVA coating that decreased the apparent EVs velocity. These results disproved the hypothesis
359 that the broad peaks observed came from EVs adsorption to the silica capillary wall. The large
360 peaks of EVs were most likely the result of a large size distribution of EVs ($153 \text{ nm} \pm 60$
361 nm , obtained from three measurements of the same sample). It can also be observed from
362 Figs. 1 and 2 that the longer the migration time of EVs is, the more the spikes on EVs' peaks
363 can be visualized. The EV standards (bovine milk-derived EVs) used in this study had a high
364 purity, thus excluding the possibility of impurity-induced spikes. Indeed, our results with LC-
365 MS/MS (see Fig. S3 in ESI) showed that the major milk protein contaminants (e.g. α -s1
366 casein, α -s2 casein, β -casein and κ -casein) as well as some whey milk proteins such as α -
367 Lactalbumin, serum albumin, etc.) were not detected in the EVs standards. Furthermore, the
368 TEM pictures for bovine-milk derived EVs with negative staining by uranyl acetate proved
369 again the high purity of EVs with the absence of the contaminant protein traces in the TEM
370 images (Fig. S4 in ESI). The appearance of spikes during the CE of nanometric entities was
371 already discussed in other studies on nanoparticles and was frequently related to the formation
372 of aggregates [30, 31]. The particle aggregates can lead to some unwanted detector response
373 (i.e. spike signals) due to the light scattering when passing through the detector [32, 33]. This
374 common problem observed with nanoparticles was also observed during the CE of liposomes
375 [34]. Interestingly, another recent work on CE-UV of EVs also revealed the presence of

376 spikes during electrophoresis [18]. Since EVs suspended in PBS were injected to the CE-LIF,
377 the presence of PBS in the sample plugs (accounting for 10 % of the total capillary volume)
378 are likely to produce local Joule heating under a high electrical field due to its high
379 conductivity. The slower the migration of EVs in PBS under high voltages is, the longer EVs
380 suffer from this local heating inside the capillary, which in turn provokes more spike-reflected
381 aggregation. Due to the selectivity offered by LIF detection, only the peaks of EVs and those
382 of fluorophore appeared in the electropherogram (see Fig. 1), allowing us to tolerate larger
383 injection volumes. Our experimental data obtained with injection volumes from 2 % to 20 %
384 of the total capillary volume (see Fig. S5 in ESI) revealed that an improvement of peak height
385 was observed with an increase in injection volume, regardless of the tested sample matrix (i.e.
386 PBS or 90 mM Tris/Ches). At large injection volumes of 15 and 20 %, the augmentation of
387 peak intensity led to peak distortion where the signal did not drop to the normal baseline after
388 the EVs peak. Furthermore, the distance between the EVs peak and the fluorophore-induced
389 plateau became much closer at injection volumes of 15-20 %, inducing more risk of peak
390 overlapping upon inevitable increase in fluorescent signal over time (see section below). An
391 injection volume of 10 % was found to be optimal, offering high signal intensity compared to
392 that for the case of 2-3 % as in conventional hydrodynamic injection for CE, while
393 maintaining sufficiently high separation resolution between EVs' and fluorophore's signals.
394 Note also that, with the pioneering work on electrophoretic separation of EVs, we
395 encountered more constraints than with the CE of nanoparticles (at least to our experience),
396 notably more strict conditions for EVs stability, poorer signal intensity, and the high ionic-
397 strength matrix required for biological entities which hinders efficient stacking. A
398 compromise CE condition was therefore established taking into consideration all these
399 constraints.

400

401 **3.3. Matrix removal strategy**

402 To avoid the aforementioned undesirable phenomenon during CE-LIF of EVs, two matrix
403 cleanup approaches were tested, i) centrifugal filtration using Nanosep with Omega
404 Membrane 3K, which was inspired from our previous work on matrix removal after
405 fluorescent peptide labeling [35] and ii) EVs filtration with commercial Exosome Spin
406 Columns (MW 3000) (see Fig. 3). In both cases, the EVs were recovered in the BGE. Both
407 approaches offered efficient removal of redundant CSFA-SE, reflected by the absence of the
408 peaks of fluorescent dyes. With the centrifugal filtration (Fig. 3B) multiple spikes were still
409 detected. The aggregation of EVs was still induced in this case, presumably due to the
410 centrifugal force at 5000 rpm required to eliminate the PBS ions through the 3K filter.
411 However, such spikes were not observed when the sample was filtered with the Spin Column
412 (Fig 3C). Furthermore, unsatisfactory EVs recovery (less than 60%) was obtained with the
413 centrifugal filtration approach, compared to that achieved with the Spin Column-based
414 alternative (75 % recovery, with deviation less than 5 % for a repeatability test on 4 EV
415 samples), presumably due to EVs sticking to the NanoSep filter membranes [36]. A similar
416 observation on low EVs recovery and reproducibility after filtration was also made in a recent
417 work on CE-UV separation of EVs [18].

418

419 In a related context, another challenge encountered was to minimize or eliminate the lysis of
420 EVs during analysis. Several studies have shown that EVs are stable under isotonic and
421 hypotonic solutions [37, 38]. At the same time, if the IS (or conductivity) of the EVs sample
422 matrix is higher than that of the BGE, this would lead to unfavorable de-stacking of EVs
423 during CE-LIF with degraded peak shape and detection sensitivity. To find a compromise,
424 matrix substitution after the Spin Column-based filtration was implemented with water and
425 Tris / CHES having IS from 5 to 90 mM. The respective electropherograms using the

426 optimized BGE are shown in Fig. 4. The best signal of EVs was achieved for the sample
427 matrix composed of Tris / CHES IS 90 mM. The signal-to-noise ratios for EVs peaks dropped
428 from 524 to 89 with IS decreasing from 90 mM to 0 mM (DI water). Compared to other more
429 diluted sample matrices, the 90 mM Tris / CHES did not produce any stacking effect since
430 the matrix shares the same composition and concentration as the BGE employed. On the other
431 hand, the rate of EVs lysis may be slowed down thanks to the IS being closer to isotonic
432 conditions, resulting in a higher signal for EVs even without stacking effect. Sample matrices
433 composed of Tris / CHES at higher IS (up to 240 mM) were also tested, but unsatisfactory
434 data were obtained (data not shown) due to the unfavorable de-stacking with broader peaks
435 when the IS of the sample matrix was higher than that of the BGE. The salient performance
436 data obtained from these optimized conditions are shown in Table 1. The best detection limit
437 for EVs achieved using the developed CE-LIF method reached approximately 8×10^9 EVs /
438 mL whereas the calibration curve was acquired up to 1.20×10^{11} EVs / mL. The correlation
439 between EVs concentrations and peak areas ($R^2 = 0.968$) was not optimal. It was nevertheless
440 deemed satisfactory, taking into consideration that it comprises all the operational errors
441 accumulated from the different steps, including EVs labeling, buffer substitution,
442 electrokinetic separation and LIF detection. In the recent work on CE-UV of EVs [18], the
443 linear correlation achieved was also far from optimal ($R^2 = 0.81$), confirming the challenges
444 currently encountered with electrokinetic separation of EVs. Note that the working EVs
445 volume of 40 μ L during the buffer substitution was at the lower limit of the recommended
446 range (20-100 μ L) for Exosome Spin columns, which in turn may lead to some dilution
447 errors. Larger working volumes were not available due to limited EVs concentrations and
448 limited initial sample volumes. Better performance would nevertheless be expected when
449 working with more concentrated EVs samples. To minimize fluorescent signal deviation due
450 to sample degradation over time after buffer substitution (evidenced by reappearance of

451 fluorophore signals in the electropherogram of Fig. S6), a calibration curve was made with
452 four samples of different concentrations prepared in parallel and analyzed promptly within the
453 same day. Excellent intermediate precision was achieved for migration times (RSD < 0.6%)
454 whereas a satisfactory one was obtained for peak areas (RSD < 5%).

455

456 **3.4. Electrokinetic distribution of EVs from different animal and human origins**

457 *3.4.1. EVs purified with SEC or ultracentrifugation*

458 Batches of EVs isolated from different animal and human origins using the established
459 method (i.e. SEC and ultracentrifugation) were analyzed with our optimized CE-LIF method
460 to demonstrate its potential in distinguishing EVs subpopulations based upon their
461 electrophoretic mobilities (see Fig. 5). The EOF was measured before and after each EVs
462 sample analysis and was shown to be remarkably stable (RSD less than 0.5 % over the whole
463 analysis series). The difference in migration times observed between different EVs
464 populations hence came purely from variation in their electrophoretic mobilities. The size
465 distributions of the EVs isolates measured with NTA were also included in Fig. 5 for cross
466 comparison with results obtained with CE-LIF. To interpret further the obtained results, our
467 initial efforts to related migration behavior of EVs to their physicochemical characteristics
468 (notably size, charge, charge/size ratio and shape) were made based on previous studies on
469 CE of nanoparticles (NPs). Both EVs and NPs were thought to share similar size and charge
470 characteristics. After this deep investigation we came to the conclusion that the dependency of
471 NPs' electrophoretic mobilities on their size, charge, charge-to-size ratio and shape cannot be
472 determined by a general rule, but was rather possible only for very specific situations and
473 under some specific conditions [39-42]. Indeed, many parameters should be well considered
474 and defined before a clear correlation between the electrophoretic mobilities of NPs and one
475 of their particular characteristics can be established. Parameters such as BGE ionic strength,

476 pH and composition, applied electrical field, injected amount of NPs etc. were found to have
477 impacts on NPs' electrophoretic mobilities ([43] and other references listed therein). This
478 makes it very difficult to rule out the dependency of NPs electrophoretic mobilities on a single
479 parameter. In the case of EVs, the situation is even more complicated, since their size
480 distributions are broader and different sub-populations can co-exist (as reflected by NTA
481 data). With bovine milk-derived EVs (Fig. 5A) one main peak was detected with CE-LIF and
482 NTA, evidencing a low degree of polydispersity. A large size distribution of $175 \text{ nm} \pm 60 \text{ nm}$
483 was observed in this case according to NTA measurements. This observation is contrary to the
484 case of CE of nanoparticles reported by Jones *et al.*, in which sharp peaks reflected different
485 particle populations, but each having a narrow particle size distribution [44]. A low degree of
486 polydispersity however was not the case with pony plasma-derived EVs (Fig. 5B) or serum-
487 derived EVs (Fig. 5C) where two subpopulations were clearly identified with CE-LIF, and
488 several size-based peaks were observed with NTA. An interesting observation was made on
489 human plasma-derived EVs (Fig. 5D), where NTA data demonstrated a relatively
490 homogeneous size distribution whereas two equivalent subpopulations were revealed with
491 CE-LIF, implying some pronounced population heterogeneity from the human EVs source.
492 While a conclusion on the reason behind the different profiles obtained with CE-LIF and
493 NTA cannot be made at this stage of proof-of-concept for electrokinetic characterization of
494 EVs, we assumed that this was due to different origins of EVs. EVs from different origins
495 probably have different proteins / biomolecules on their surface and also different shapes that
496 may influence their electrophoretic mobilities. Note also that EVs can exhibit shape variations
497 in different BGE conditions, similar to the behavior of cells. Lysis of EVs can also occur,
498 requiring a careful and restricted selection of BGE composition and ionic strength. The
499 application of a high electrical field, as suggested by Jones *et al.* and d'Orlyé *et al.* for better
500 NPs separations [40, 44], could not be utilized for EVs because it would provoke lysis. As a

501 result, when applying these to the CE-LIF separations of EVs from different origins (Fig. 5),
502 it was difficult to draw any conclusion. A deeper characterization study would therefore be
503 needed to elucidate the EVs electrophoretic migration behavior, using EVs with a lower
504 degree of polydispersity and narrower size distribution. Such pure EVs nevertheless are not
505 yet available with existing methods for EV purification.

506

507 *3.4.2. EVs isolated with monolithic disks via immunoaffinity chromatography*

508 Our CE-LIF approach was used to verify the presence of subpopulation of EVs isolated with
509 our recent method based on functionalized monolithic disks. The reported isolation protocol
510 using anti-human CD61 antibody [17] was herein extended using monolithic disk
511 immobilized with monoclonal anti-human CD9 antibody. While monolithic disks
512 immobilized with anti-CD61 antibody allow collection of platelet-derived EVs with sizes of
513 30-130 nm [17], those immobilized with anti-CD9 antibody were expected to capture more
514 specifically a potential EV subtype historically claimed as “exosomes”, since CD9 is a
515 tetraspanin that is thought to be enriched specifically in exosomes [45]. Note that according to
516 the MISEV guidelines from ISEV, it is still not possible to propose a specific and universal
517 marker of one or the other type of EVs. Distinct elutions from these two monolithic disks,
518 using either ammonium hydroxide or sodium bicarbonate-carbonate as eluents are shown in
519 Fig. 6. For comparison purpose, some NTA data for such elutions were provided in Fig. S7 in
520 the ESI. From the electropherograms, three EV subpopulations from each of these elutions ()
521 were detected with CE-LIF. Three fractions were also detected with asymmetrical flow field-
522 flow fractionation (AsFIFFF) in our previous work [17], proving the concordance of the
523 results obtained with CE-LIF. Based on the CE-LIF signal intensity, the highest concentration
524 was found for the fraction with the longest migration time (17 min). . When monolithic disks
525 immobilized with anti-CD9 antibody were employed, the signal of the second peak zone (10-

526 12 min) became more intense (Fig. 6D). As already discussed above, no conclusion on the
527 precise size and charge of EV subpopulations visualized with CE-LIF could be made due to
528 the lack of reference data for the fractions collected after the elution step. In an effort to give a
529 deeper insight into EVs after the monolithic affinity step, AsFIFFF was employed to further
530 fractionate these eluents. Our CE-LIF approach was used to verify the quality of these EV
531 fractions collected with AsFIFFF. .. Due to considerably lower EV concentrations in the
532 AsFIFFF fractions compared to the whole monolithic disk isolates, lyophilization was used to
533 enrich EVs prior to CE-LIF. This process was shown not to change the properties of EVs, or
534 at least their physical characteristics [46]. The electropherograms for the AsFIFFF fractions
535 expected to contain small EVs were shown in dashed lines in Figs. 6C and D. As can be
536 seen, the presence of EVs in the AsFIFFF fractions (Fig. 6) was confirmed by the
537 superposition of their profiles on those of the bulk collects.. Based on our results, the CE-LIF
538 shows a real potential in distinguishing different EV subpopulations from highly specific EV
539 isolates, which provides crucial information for future studies in the EV field. The developed
540 CE-LIF method visualized the EVs distribution in AsFIFFF fractions and demonstrated that
541 further optimization of the AsFIFFF method would be needed to obtain purer fractions of the
542 EV subpopulations. Interestingly, higher LIF intensities were always observed on carbonate-
543 bicarbonate elutions (Figs. 6 C, D) compared to those of ammonium hydroxide ones (Figs. A,
544 B), regardless of the antibody used. This led us to a deeper study on CFDA-SE labelling in
545 different media (see Fig. S6 in the ESI), which confirmed the less efficient labelling under an
546 ammonium hydroxide medium due to unwanted conversion of CFDA-SE into side products in
547 the presence of ammonium / amine groups.

548

549 **4. Conclusion remarks**

550 We successfully developed a fast and reliable CE-LIF method for the determination of
551 labelled EVs, providing the first evidence that CE can be applied to distinguish EVs
552 subpopulations from EV isolates, based on their electrophoretic mobilities. This new tool for
553 the elucidation of electrokinetic distribution of EV populations adds valuable information to
554 commonly-used size-based physical techniques such as NTA and transmission electron
555 microscopy. The applicability of the CE-LIF approach was successfully demonstrated for
556 tracing of EVs from different origins, as well as for quality control of EVs after isolation with
557 different methods including monolithic disks and subpopulation fractionation with AsFIFFF.
558 Inclusion of a forefront isolation step from highly complex biofluids into an integrated
559 microfluidic platform is now envisaged for the electrokinetic characterization of EV
560 subpopulations with tiny sample volumes and low EV concentrations. Translation of
561 batchwise EV sample treatment protocol into an integrated microfluidic platform is also
562 desirable to reduce operation time and avoid cross contamination and EV loss. Prospective
563 work to establish a solid theoretical background for the electrokinetic profiling of EVs will
564 also be implemented when EVs with a better degree of polydispersity and narrower size (and
565 charge) distribution could be obtained through improvement of EV purification technologies.

566

567 **Acknowledgement**

568 This work has been financially supported by the Institut Universitaire de France (for M.
569 Taverna, senior member). The doctoral scholarship for Marco Morani was supported by the
570 doctoral school 2MIB (Sciences Chimiques: Molécules, Matériaux, Instrumentation et
571 Biosystèmes) – University Paris Saclay. We thank Ms. Oihana Inda-Arsa for preliminary
572 explorations in CE-UV and CE-LIF. Dr. Hervé Hillaireau and Magali Noiray from Institute
573 Galien Paris Sud – University Paris Saclay are acknowledged for their help and support in
574 NTA measurements. We thank Mr. Edward Mitchell for English grammar corrections.

575 Financial support (E.M. and M.-L.R.) was also provided by the Research Council for Natural
576 Sciences and Engineering, Academy of Finland (grant No 1311369)

577 The authors have declared no conflict of interest.

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600 **References:**

- 601 [1] G. van Niel, G. D'Angelo, G. Raposo, Shedding light on the cell biology of extracellular
602 vesicles, *Nat. Rev. Mol. Cell Biol* 19 (2018) 213-228.
- 603 [2] G. Raposo, W. Stoorvogel, Extracellular vesicles: Exosomes, microvesicles, and friends, *J.*
604 *Cell Biol.*, 200 (2013) 373-383.
- 605 [3] H.C. Bu, D.G. He, X.X. He, K.M. Wang, Exosomes: Isolation, Analysis, and Applications
606 in Cancer Detection and Therapy, *Chembiochem*, 20 (2019) 451-461.
- 607 [4] M.T. Guo, A. Rotem, J.A. Heyman, D.A. Weitz, Droplet microfluidics for high-
608 throughput biological assays, *Lab on a Chip*, 12 (2012) 2146-2155.
- 609 [5] J. Howitt, A.F. Hill, Exosomes in the Pathology of Neurodegenerative Diseases, *Journal of*
610 *Biological Chemistry*, 291 (2016) 26589-26597.
- 611 [6] H.L. Shao, H. Im, C.M. Castro, X. Breakefield, R. Weissleder, H.H. Lee, New
612 Technologies for Analysis of Extracellular Vesicles, *Chemical Reviews*, 118 (2018)
613 1917-1950.
- 614 [7] E.H. Koritzinsky, J.M. Street, R.A. Star, P.S.T. Yuen, Quantification of Exosomes, *J. Cell.*
615 *Physiol.*, 232 (2017) 1587-1590.
- 616 [8] R. Szatanek, M. Baj-Krzyworzeka, J. Zimoch, M. Lekka, M. Siedlar, J. Baran, The
617 Methods of Choice for Extracellular Vesicles (EVs) Characterization, *Int. J. Mol. Sci.*, 18
618 (2017).
- 619 [9] U. Erdbrugger, J. Lannigan, Analytical Challenges of Extracellular Vesicle Detection: A
620 Comparison of Different Techniques, *Cytometry Part A*, 89A (2016) 123-134.
- 621 [10] S. Biosciences, FluoroCet exosome quantitation kit [https://www.systembio.com/wp-](https://www.systembio.com/wp-content/uploads/MANUAL_FCET96A-1-1.pdf)
622 [content/uploads/MANUAL_FCET96A-1-1.pdf](https://www.systembio.com/wp-content/uploads/MANUAL_FCET96A-1-1.pdf), (2017).
- 623 [11] T. Hikita, M. Miyata, R. Watanabe, C. Oneyama, Sensitive and rapid quantification of
624 exosomes by fusing luciferase to exosome marker proteins, *Sci. Reports*, 8 (2018).

- 625 [12] M. Al Ahmad, Electrical Detection, Identification, and Quantification of Exosomes, *Ieee*
626 *Access*, 6 (2018) 22817-22826.
- 627 [13] L. Trapiella-Alfonso, G. Ramirez-Garcia, F. d'Orlye, A. Varenne, Electromigration
628 separation methodologies for the characterization of nanoparticles and the evaluation of
629 their behaviour in biological systems, *Trac-Trends Anal. Chem.*, 84 (2016) 121-130.
- 630 [14] T. Akagi, K. Kato, M. Kobayashi, N. Kosaka, T. Ochiya, T. Ichiki, On-Chip
631 Immunoelectrophoresis of Extracellular Vesicles Released from Human Breast Cancer
632 Cells, *Plos One*, 10 (2015).
- 633 [15] K. Kato, M. Kobayashi, N. Hanamura, T. Akagi, N. Kosaka, T. Ochiya, T. Ichiki,
634 Electrokinetic Evaluation of Individual Exosomes by On-Chip Microcapillary
635 Electrophoresis with Laser Dark-Field Microscopy, *Jpn. J. Appl. Phys.*, 52 (2013).
- 636 [16] T. Akagi, K. Kato, N. Hanamura, M. Kobayashi, T. Ichiki, Evaluation of desialylation
637 effect on zeta potential of extracellular vesicles secreted from human prostate cancer cells
638 by on-chip microcapillary electrophoresis, *Jpn. J. Appl. Phys.*, 53 (2014).
- 639 [17] E. Multia, C.J.Y. Tear, M. Palviainen, P. Siljander, M.-L. Riekkola, Fast isolation of
640 highly specific population of platelet-derived extracellular vesicles from blood plasma by
641 affinity monolithic column, immobilized with anti-human CD61 antibody, *Anal. Chim.*
642 *Acta*, 1091 (2019) 160-168.
- 643 [18] M. Piotrowska, K. Ciura, M. Zalewska, M. Dawid, B. Correia, P. Sawicka, B. Lewczuk,
644 J. Kasprzyk, L. Sola, W. Piekoszewski, B. Wielgomas, K. Waleron, S. Dziomba,
645 Capillary zone electrophoresis of bacterial extracellular vesicles: A proof of concept, *J.*
646 *Chromatogr. A*, (2020) 461047.
- 647 [19] O.H. Lowry, N.J. Rosebrough, A.L. Farr, R.J. Randall, Protein measurement with the
648 folin phenol reagent, *J. Biol. Chem.*, 193 (1951) 265-275.

- 649 [20] M. Puhka, M.E. Nordberg, S. Valkonen, A. Rannikko, O. Kallioniemi, P. Siljander, T.M.
650 af Hallstrom, KeepEX, a simple dilution protocol for improving extracellular vesicle
651 yields from urine, *Eur. J. Pharm. Sci.*, 98 (2017) 30-39.
- 652 [21] A. Hellqvist, Y. Hedeland, C. Pettersson, Evaluation of electroosmotic markers in
653 aqueous and nonaqueous capillary electrophoresis, *Electrophoresis*, 34 (2013) 3252-3259.
- 654 [22] A. Hoshino, B. Costa-Silva, T.L. Shen, G. Rodrigues, A. Hashimoto, M.T. Mark, H.
655 Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. Williams, N. Soplop, K.
656 Uryu, L. Pharmed, T. King, L. Bojmar, A.E. Davies, Y. Ararso, T. Zhang, H. Zhang, J.
657 Hernandez, J.M. Weiss, V.D. Dumont-Cole, K. Kramer, L.H. Wexler, A. Narendran,
658 G.K. Schwartz, J.H. Healey, P. Sandstrom, K.J. Labori, E.H. Kure, P.M. Grandgenett,
659 M.A. Hollingsworth, M. de Sousa, S. Kaur, M. Jain, K. Mallya, S.K. Batra, W.R.
660 Jarnagin, M.S. Brady, O. Fodstad, V. Muller, K. Pantel, A.J. Minn, M.J. Bissell, B.A.
661 Garcia, Y. Kang, V.K. Rajasekhar, C.M. Ghajar, I. Matei, H. Peinado, J. Bromberg, D.
662 Lyden, Tumour exosome integrins determine organotropic metastasis, *Nature*, 527 (2015)
663 329-+.
- 664 [23] H.D. Roberts-Dalton, A. Cocks, J.M. Falcon-Perez, E.J. Sayers, J.P. Webber, P. Watson,
665 A. Clayton, A.T. Jones, Fluorescence labelling of extracellular vesicles using a novel
666 thiol-based strategy for quantitative analysis of cellular delivery and intracellular traffic,
667 *Nanoscale*, 9 (2017) 13693-13706.
- 668 [24] J. Lannigan, U. Erdbruegger, Imaging flow cytometry for the characterization of
669 extracellular vesicles, *Methods*, 112 (2017) 55-67.
- 670 [25] A. Morales-Kastresana, B. Telford, T.A. Musich, K. McKinnon, C. Clayborne, Z. Braig,
671 A. Rosner, T. Demberg, D.C. Watson, T.S. Karpova, G.J. Freeman, R.H. DeKruyff, G.N.
672 Pavlakis, M. Terabe, M. Robert-Guroff, J.A. Berzofsky, J.C. Jones, Labeling
673 Extracellular Vesicles for Nanoscale Flow Cytometry, *Sci. Rep.*, 7 (2017).

- 674 [26] M. Dehghani, S.M. Gulvin, J. Flax, T.R. Gaborski, Exosome labeling by lipophilic dye
675 PKH26 results in significant increase in vesicle size, bioRxiv, (2019) 532028.
- 676 [27] X.Q. Wang, X.M. Duan, L.H. Liu, Y.Q. Fang, Y. Tan, Carboxyfluorescein diacetate
677 succinimidyl ester fluorescent dye for cell Labeling, *Acta Biochim. Biophys. Sin.*, 37
678 (2005) 379-385.
- 679 [28] M. Morani, M. Taverna, T.D. Mai, A fresh look into background electrolyte selection for
680 capillary electrophoresis-laser induced fluorescence of peptides and proteins,
681 *Electrophoresis*, 40 (2019) 2618-2624.
- 682 [29] H.T. Banks, A. Choi, T. Huffman, J. Nardini, L. Poag, W.C. Thompson, Quantifying
683 CFSE label decay in flow cytometry data, *Appl. Math. Lett.*, 26 (2013) 571-577.
- 684 [30] C. Quang, S.L. Petersen, G.R. Ducatte, N.E. Ballou, Characterization and separation of
685 inorganic fine particles by capillary electrophoresis with an indifferent electrolyte system,
686 *Journal of Chromatography A*, 732 (1996) 377-384.
- 687 [31] S.L. Petersen, N.E. Ballou, Separation of micrometer-size oxide particles by capillary
688 zone electrophoresis, *Journal of Chromatography A*, 834 (1999) 445-452.
- 689 [32] S. Dziomba, K. Ciura, B. Correia, B. Wielgomas, Stabilization and isotachopheresis of
690 unmodified gold nanoparticles in capillary electrophoresis, *Analytica Chimica Acta*, 1047
691 (2019) 248-256.
- 692 [33] S. Dziomba, K. Ciura, P. Kocialkowska, A. Prahl, B. Wielgomas, Gold nanoparticles
693 dispersion stability under dynamic coating conditions in capillary zone electrophoresis,
694 *Journal of Chromatography A*, 1550 (2018) 63-67.
- 695 [34] M.A. Roberts, L. LocascioBrown, W.A. MacCrehan, R.A. Durst, Liposome behavior in
696 capillary electrophoresis, *Analytical Chemistry*, 68 (1996) 3434-3440.
- 697 [35] C.C. de Lassichere, T.D. Mai, M. Otto, M. Taverna, Online Preconcentration in
698 Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to

- 699 Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal
700 Fluid, *Anal. Chem.*, 90 (2018) 2555-2563.
- 701 [36] K.E. Petersen, F. Shiri, T. White, G.T. Bardi, H. Sant, B.K. Gale, J.L. Hood, Exosome
702 Isolation: Cyclical Electrical Field Flow Fractionation in Low-Ionic-Strength Fluids,
703 *Analytical Chemistry*, 90 (2018) 12783-12790.
- 704 [37] E. Willms, H.J. Johansson, I. Mager, Y. Lee, K.E.M. Blomberg, M. Sadik, A. Alaarg,
705 C.I.E. Smith, J. Lehtio, S.E.L. Andaloussi, M.J.A. Wood, P. Vader, Cells release
706 subpopulations of exosomes with distinct molecular and biological properties, *Sci. Rep.*,
707 6 (2016) 12.
- 708 [38] V.S. Chernyshev, R. Rachamadugu, Y.H. Tseng, D.M. Belnap, Y.L. Jia, K.J. Branch,
709 A.E. Butterfield, L.F. Pease, P.S. Bernard, M. Skliar, Size and shape characterization of
710 hydrated and desiccated exosomes, *Anal. Bioanal. Chem.*, 407 (2015) 3285-3301.
- 711 [39] F. d'Orlye, A. Varenne, P. Gareil, Size-based characterization of nanometric cationic
712 maghemite particles using capillary zone electrophoresis, *Electrophoresis*, 29 (2008)
713 3768-3778.
- 714 [40] F. d'Orlye, A. Varenne, T. Georgelin, J.M. Siaugue, B. Teste, S. Descroix, P. Gareil,
715 Charge-based characterization of nanometric cationic bifunctional maghemite/silica
716 core/shell particles by capillary zone electrophoresis, *Electrophoresis*, 30 (2009) 2572-
717 2582.
- 718 [41] F.K. Liu, F.H. Ko, P.W. Huang, C.H. Wu, T.C. Chu, Studying the size/shape separation
719 and optical properties of silver nanoparticles by capillary electrophoresis, *J. Chromatogr.*
720 *A*, 1062 (2005) 139-145.
- 721 [42] N.G. Vanifatova, B.Y. Spivakov, J. Mattusch, U. Franck, R. Wennrich, Investigation of
722 iron oxide nanoparticles by capillary zone electrophoresis, *Talanta*, 66 (2005) 605-610.

- 723 [43] U. Pyell, Characterization of nanoparticles by capillary electromigration separation
724 techniques, *Electrophoresis*, 31 (2010) 814-831.
- 725 [44] H.K. Jones, N.E. Ballou, Separations of chemically different particles by capillary
726 electrophoresis, *Anal. Chem.*, 62 (1990) 2484-2490.
- 727 [45] J. Kowal, G. Arras, M. Colombo, M. Jouve, J.P. Morath, B. Primdal-Bengtson, F. Dingli,
728 D. Loew, M. Tkach, C. Théry, Proteomic comparison defines novel markers to
729 characterize heterogeneous populations of extracellular vesicle subtypes, *PNAS*, 113
730 (2016) E968.
- 731 [46] A.E. Russell, A. Sneider, K.W. Witwer, P. Bergese, S.N. Bhattacharyya, A. Cocks, E.
732 Cocucci, U. Erdbrügger, J.M. Falcon-Perez, D.W. Freeman, T.M. Gallagher, S. Hu, Y.
733 Huang, S.M. Jay, S.-i. Kano, G. Lavieu, A. Leszczynska, A.M. Llorente, Q. Lu, V.
734 Mahairaki, D.C. Muth, N. Noren Hooten, M. Ostrowski, I. Prada, S. Sahoo, T.H.
735 Schøyen, L. Sheng, D. Tesch, G. Van Niel, R.E. Vandenbroucke, F.J. Verweij, A.V.
736 Villar, M. Wauben, A.M. Wehman, H. Yin, D.R.F. Carter, P. Vader, Biological
737 membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position
738 paper arising from the ISEV membranes and EVs workshop, *J. Extracell. Vesicles*, 8
739 (2019) 1684862.
- 740
- 741
- 742
- 743
- 744
- 745
- 746

747 **Table 1:** Calibration range, coefficient of determination (R^2) for linearity, limit of detection
748 (LOD) and repeatability ($n = 3$) for the CE-LIF determination of fluorescently labelled
749 EVs

Calibration range (EVs / mL) ^a	R^2	LOD (EVs / mL) ^b	RSD (%) migration times	RSD (%) peak areas
$1.22 \times 10^{10} - 12 \times 10^{10}$	0,968	7.86×10^9	0.6	4.3

750 ^a 4 concentrations.

751 ^b Based on peak heights corresponding to $S/N = 3$

752

753

754

755

756

757

758

759

760

761

762

763

764

765

766

767

768

769

770 **Figure captions:**

771 Fig. 1. CE-LIF of EVs (in PBS) derivatized with CFDA-SE, using ISF BGE Tris / CHES
772 (pH 8.4) at different ionic strengths: A) 50 mM; B) 90 mM and C) 150 mM. Other
773 CE conditions: uncoated fused silica capillary with I.D. of 50 μm , effective length
774 (l_{eff}) of 50.2 cm and total length (L_{tot}) of 60.2 cm; Applied voltage: +25 kV;
775 hydrodynamic injection at 3.4 kPa for 2 min. LIF detection with $\lambda_{\text{ex}} = 488 \text{ nm}$, λ_{em} :
776 520 nm.

777
778 Fig. 2. CE-LIF of EVs (in PBS) derivatized with CFDA-SE in PVA coated capillary A)
779 I.D. of 50 μm , effective length (l_{eff}) of 10 cm and total length (L_{tot}) of 60.2 cm using
780 ISF BGE composed of Tris / CHES (IS 50 mM, pH 8.4); B) and C) I.D. of 50 μm ,
781 effective length (l_{eff}) of 50.2 cm and total length (L_{tot}) of 60.2 cm using ISF BGE
782 composed of Tris / CHES IS 50 mM and 90 mM (pH 8.4) respectively. Other CE
783 conditions: -25 kV; $\lambda_{\text{ex}} = 488 \text{ nm}$, λ_{em} : 520 nm.

784
785 Fig. 3. CE-LIF of fluorescently labeled EVs (A) without filtration (in PBS); (B) after
786 matrix removal with Nanosep unit using a Omega 3K membrane and reconstitution
787 in Tris / CHES (IS 90 mM, pH 8.4); and (C) with Exosome Spin Columns (MW
788 3000) and reconstitution in Tris / CHES 90 mM at pH 8.4. BGE: Tris / CHES (IS
789 90 mM, pH 8.4). Other CE conditions as described in Fig. 1.

790
791 Fig. 4. CE-LIF of fluorescently labeled EVs after matrix substitution with Exosome Spin
792 Column (MW 3000) by Tris / CHES (pH 8.4) at different ionic strengths: A) 90
793 mM; B) 50 mM; C) 20 mM; D) 5 mM and E) DI water. Other CE conditions as
794 described in Fig. 3.

795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812

Fig. 5. CE-LIF electropherograms vs. NTA profiles for fluorescently labeled EVs (after matrix removal with Exosome Spin Columns (MW 3000) and reconstitution in Tris / CHES 90 mM at pH 8.4). The EVs were purified from A) bovine milk; B) pony plasma; C) pony serum and D) human plasma. BGE: Tris / CHES (IS 90 mM, pH 8.4). Other CE conditions as described in Fig. 1.

Fig. 6 CE-LIF of fluorescently labeled EVs isolated with affinity monolithic disks (continuous lines) after matrix substitution into Tris / CHES 90 mM (pH 8.4) with Exosome Spin Columns (MW 3000). The dashed lines represent the EV distributions in fractions further purified with AsFIFFF after the elution step. EVs elution from monolithic disks under alkaline conditions (pH 11.3) was performed with: (A) (B) ammonium hydroxide; (C) (D) sodium bicarbonate-carbonate. Monolithic disks were immobilized with: (A)(C) anti-human CD61; (B)(D) anti-human CD9. Other CE conditions as described in Fig. 1




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

